Page last updated: 2024-12-11

fumagillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
NosemagenusA genus of parasitic FUNGI in the family Nosematidae. Some species are pathogenic for invertebrates of economic importance while others are being researched for possible roles in controlling pest INSECTS. They are also pathogenic in humans.[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID6917655
CHEMBL ID32838
CHEBI ID48635
SCHEMBL ID8130
SCHEMBL ID15263952
MeSH IDM0086333

Synonyms (82)

Synonym
zgn-201
flisint
sr-90144
antibiotic obtained from cultures of aspergillus fumigatus, or the same substance produced by any other means
2,4,6,8-decatetraenedioic acid, mono(5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl) ester, (3r-(3alp
fumagillin [inn:ban:dcf]
fumagillinum [inn-latin]
ccris 9025
fumagilina [inn-spanish]
c26h34o7
einecs 245-433-8
nsc 9168
fumagilline [inn-french]
fumagillina [dcit]
2,4,6,8-decatetraenedioic acid, mono(4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2.5)oct-6-yl) ester (van)
amebacillin
amebacilin
nsc-9168
nsc9168 ,
fugillin
fugilin
u 5762
fumagillin dch
fumidil
h-3
FUMAGILLIN ,
23110-15-8
DB02640
NCGC00163699-01
NCGC00163699-02
CHEBI:48635 ,
2,4,6,8-decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester
fumagillinum
fumagilina
(2e,4e,6e,8e)-10-({(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl}oxy)-10-oxodeca-2,4,6,8-tetraenoic acid
fumagilline
CHEMBL32838 ,
(-)-fumagillin
bdbm50113436
LMPR0103060003
NCGC00255568-01
dtxsid7040736 ,
cas-23110-15-8
dtxcid5020736
tox21_302410
tox21_112066
fumagillina
unii-7ow73204u1
7ow73204u1 ,
S7784
HY-B0751
NGGMYCMLYOUNGM-CSDLUJIJSA-N
SCHEMBL8130
fumagillin [inn]
fumagillin [who-dd]
2,4,6,8-decatetraenedioic acid, mono(5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl) ester, (3r- (3.alpha.,4.alpha.(2r*,3r*),5.beta.,6.beta.(2e,4e,6e,8e)))-
2,4,6,8-decatetraenedioic acid, 1-((3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl) ester, (2e,4e,6e,8e)-
fumagillin [mart.]
2,4,6,8-decatetraenedioic acid, mono((3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl) ester, (2e,4e,6e,8e)-
fumagillin [mi]
2,4,6,8-decatetraenedioic acid, mono(4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2.5)oct-6-yl) ester
(2e,4e,6e,8e)-10-(((3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl)oxy)-10-oxodeca-2,4,6,8-tetraenoic acid
SCHEMBL15263952
(2e,4e,6e,8e)-mono[(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] 2,4,6,8-decatetraenedioic acid ester
HB3901
AKOS024456768
BS-16576
127913-45-5
EX-A2890
Q120199
(2e,4e,6e,8e)-10-(((3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl)oxy)-10-oxodeca-2,4,6,8-tetraeno
NCGC00163699-07
D81922
2,4,6,8-decatetraenedioic acid, mono[(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, (2e,4e,6e,8e)-
AC-35866
fumagilina (inn-spanish)
2,4,6,8-decatetraenedioic acid, mono(5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl) ester, (3r-(3alpha,4alpha(2r*,3r*),5beta,6beta(2e,4e,6e,8e)))-
fumagillin (mart.)
fumagilline (inn-french)
p01ax10
fumagillinum (inn-latin)
(2e,4e,6e,8e)-10-(((3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)oct-6-yl)oxy)-10-oxodeca-2,4,6,8-tetraenoic acid

Research Excerpts

Overview

Fumagillin 1 is a meroterpenoid from Aspergillus fumigatus that is known for its anti-angiogenic activity by binding to human methionine aminopeptidase 2. It is an effective treatment against Enterocytozoon bieneusi.

ExcerptReferenceRelevance
"Fumagillin is a mycotoxin produced, above all, by the saprophytic filamentous fungus "( Fumagillin, a Mycotoxin of
Abad-Diaz de Cerio, A; Alonso, RM; Gonzalez, O; Guruceaga, X; Hernando, FL; Perez-Cuesta, U; Ramirez-Garcia, A; Rementeria, A, 2019
)
3.4
"Fumagillin 1 is a meroterpenoid from Aspergillus fumigatus that is known for its anti-angiogenic activity by binding to human methionine aminopeptidase 2. "( The fumagillin biosynthetic gene cluster in Aspergillus fumigatus encodes a cryptic terpene cyclase involved in the formation of β-trans-bergamotene.
Calvo, AM; Chooi, YH; Dhingra, S; Lin, HC; Tang, Y; Xu, W, 2013
)
2.39
"Fumagillin is a potent fungal metabolite first isolated from Aspergillus fumigatus. "( Fumagillin: an overview of recent scientific advances and their significance for apiculture.
Curtis, JM; Ibrahim, A; Pernal, SF; Thompson, TS; van den Heever, JP, 2014
)
3.29
"Fumagillin is an inhibitor of type 2 methionine aminopeptidase that can block blood vessel formation, but its molecular mechanism and therapeutic value in colon cancer still remain to be elucidated. "( Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis.
Hou, L; Kai, K; Meihua, P; Mori, D; Takase, Y; Tokunaga, O, 2009
)
3.24
"Fumagillin is an effective treatment with an acceptable safety profile, but monitoring of tacrolimus levels is warranted."( Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients.
Champion, L; Chauvet, C; Delahousse, M; Durrbach, A; Glotz, D; Lang, P; Molina, JM; Sarfati, C, 2010
)
2.52
"Fumagillin is an effective treatment against Enterocytozoon bieneusi, one of the two main species causing the microsporidiosis involved in human diseases."( Fumagillin-induced aseptic meningoencephalitis in a kidney transplant recipient with microsporidiosis.
Audemard, A; Carluer, L; Castrale, C; Dargère, S; Hurault de Ligny, B; Le Bellec, ML; Lobbedez, T; Verdon, R, 2012
)
2.54
"Fumagillin is a potent anti-angiogenic drug used in cancer treatments. "( Homology modeling and calculation of the cobalt cluster charges of the Encephazlitozoon cuniculi methionine aminopeptidase, a potential target for drug design.
Biderre, C; Bontems, F; Duffieux, F; Lallemand, JY; le Floch, P; Peyret, P, 2003
)
1.76
"Fumagillin is a naturally occurring antifungal agent."( Antiangiogenic agents: studies on fumagillin and curcumin analogs.
Arbiser, JL; Bowen, JP; Ehlers, T; Furness, MS; Goldsmith, DJ; Hubbard, RB; Robinson, TP, 2005
)
1.33
"Fumagillin is a naturally secreted antibiotic of the fungus Aspergillus fumigatus. "( Evaluation of genotoxic effects of fumagillin by cytogenetic tests in vivo.
Bajic, V; Radovic, I; Stanimirovic, Z; Stevanovic, J, 2007
)
2.06
"Fumagillin is an active amebicide and anti-infective isolated from the fungus Aspergillus fumigatus. "( Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors.
Arbiser, JL; Govindarajan, B; Lefkove, B, 2007
)
3.23
"Fumagillin is an effective treatment for chronic E. "( Fumagillin treatment of intestinal microsporidiosis.
Balkan, S; Chevret, S; de Gouvello, A; Derouin, F; Gobert, JG; Molina, JM; Sarfati, C; Tourneur, M, 2002
)
3.2

Effects

Fumagillin has been previously used to treat corneal microsporidial keratitis and also identified as an angiogenesis inhibitor.

ExcerptReferenceRelevance
"Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent."( Therapeutic targets for the treatment of microsporidiosis in humans.
Han, B; Weiss, LM, 2018
)
1.2
"Fumagillin has been approved in France for its treatment."( Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study.
Laffy, B; Mahloul, N; Maillard, A; Molina, JM; Scemla, A, 2021
)
1.65
"Fumagillin has been previously used to treat corneal microsporidial keratitis and also identified as an angiogenesis inhibitor. "( Efficacy of fumagillin bicyclohexylamine on experimental corneal neovascularization in rat model.
Aşula, MF; Onur, IU; Yigit, FU, 2019
)
2.34

Actions

Fumagillin can also inhibit cancer cell proliferation, implying that MetAP2 may play a quite complex role in tumor progression.

ExcerptReferenceRelevance
"Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity."( Structure of human methionine aminopeptidase-2 complexed with fumagillin.
Clardy, J; Crews, CM; Kemp, CW; Liu, S; Widom, J, 1998
)
1.26
"Fumagillin can also inhibit cancer cell proliferation, implying that MetAP2 may play a quite complex role in tumor progression."( Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity.
Catalano, A; Procopio, A; Robuffo, I; Romano, M; Strizzi, L, 2001
)
1.03

Treatment

Treatment with fumagillin beginning two weeks after monocrotaline injury did not prevent PH but was associated with decreased right ventricular mass and decreased cardiomyocyte hypertrophy. Oral treatment with fmagillin or thiabendazole significantly reduced pathogen spore counts.

ExcerptReferenceRelevance
"Fumagillin‑treated colonies had reduced N."( Fumagillin control of Nosema ceranae (Microsporidia:Nosematidae) infection in honey bee (Hymenoptera:Apidae) colonies in Argentina.
Cagnolo, NB; Giacobino, A; Merke, J; Molineri, AI; Orellano, E; Rivero, R; Salto, C; Signorini, M, 2016
)
2.6
"The Fumagillin-treated mice had smaller tumor mass, fewer pulmonary metastases, and lower MVD-CD105 levels than control animals."( Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis.
Hou, L; Kai, K; Meihua, P; Mori, D; Takase, Y; Tokunaga, O, 2009
)
2.28
"Fumagillin-treated neutrophils showed reduced degranulation as evidenced by lower myeloperoxidase activity (P<0.019)."( Inhibition of neutrophil function following exposure to the Aspergillus fumigatus toxin fumagillin.
Fallon, JP; Kavanagh, K; Reeves, EP, 2010
)
1.3
"The Fumagillin treated tibiae had a significantly decreased callus size at day 42 and 84, less blood vessels in the early callus, a reduced histological callus size at day 10, 28 and 84, as well as an altered callus composition."( Local inhibition of angiogenesis results in an atrophic non-union in a rat osteotomy model.
Bergmann, C; Fassbender, M; Rauhe, JS; Schmidmaier, G; Strobel, C; Wildemann, B, 2011
)
0.85
"Treatment with fumagillin enhances in vitro differentiation of preadipocytes, but has only a minor effect on in vivo adipogenesis."( Effect of fumagillin on adipocyte differentiation and adipogenesis.
Christiaens, V; Lijnen, HR; Scroyen, I, 2010
)
1.1
"Treatment with fumagillin beginning two weeks after monocrotaline injury did not prevent PH but was associated with decreased right ventricular mass and decreased cardiomyocyte hypertrophy, suggesting a direct effect of fumagillin on right ventricular remodeling."( Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured rats.
Ahmad, F; Champion, HC; Kahloon, R; Kass, DJ; Loh, K; Markowski, M; Rajkumar, R; Rattigan, E; Saqi, A; Savir, A; Yu, L, 2012
)
1.04
"Treatment with fumagillin caused a selective reduction in the numbers of bromodeoxyuridine (BrdU)-positive myofibroblasts, but not type II alveolar epithelial cells, macrophages, or B- and T-lymphocytes in the lungs of bleomycin-treated mice."( Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis.
Borczuk, A; Bridges, RS; Greenberg, S; Kass, D, 2007
)
0.68
"Oral treatment with fumagillin or thiabendazole significantly reduced pathogen spore counts, whereas spore counts of grasshoppers fed with albendazole, ampicillin, chloramphenicol, griseofulvin, metronidazole, sulfadimethoxine, or tetracycline were not significantly different from the infected controls."( New insect system for testing antibiotics.
Johny, S; Lange, CE; Merisko, A; Solter, LF; Whitman, DW, 2007
)
0.65
"Oral treatment with fumagillin or thiabendazole significantly reduced pathogen spore counts (93% and 88% respectively), whereas spore counts of grasshoppers fed quinine produced a non-significant 53% reduction in spores, and those fed streptomycin a non-significant 29% increase in spores, compared to the control."( Effect of four antimicrobials against an Encephalitozoon sp. (Microsporidia) in a grasshopper host.
Johny, S; Whitman, DW, 2008
)
0.66
"Treatment with fumagillin at 60 mg/day for 14 days has promise as an effective oral treatment for E. "( Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA.
Balkan, S; Chastang, C; Cotte, L; Decazes, JM; Derouin, F; Desportes-Livage, I; Goguel, J; Maslo, C; Michiels, JF; Molina, JM; Sarfati, C; Struxiano, A, 2000
)
1.02
"Treatment with fumagillin was also associated with increases in absorption of D-xylose (P=0.003) and in Karnofsky performance scores (P<0.001) and with decreases in loperamide use (P=0.01) and total stool weight (P=0.04)."( Fumagillin treatment of intestinal microsporidiosis.
Balkan, S; Chevret, S; de Gouvello, A; Derouin, F; Gobert, JG; Molina, JM; Sarfati, C; Tourneur, M, 2002
)
2.1

Toxicity

ExcerptReferenceRelevance
" Serious adverse events were reported in 41 patients (25%), mainly thrombocytopenia (15%) and neutropenia (5%), with two haemorrhagic events leading to one death."( Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study.
Laffy, B; Mahloul, N; Maillard, A; Molina, JM; Scemla, A, 2021
)
0.93

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" No corneal or systemic toxicities were noted using the dosage and preparation employed (10 mg/ml suspension in balanced salt solution)."( Successful treatment of microsporidial keratoconjunctivitis with topical fumagillin in a patient with AIDS.
Bryan, RT; Erlandson, RA; Keenan, PC; Rosberger, DF; Schwartz, DA; Serdarevic, ON; Visvesvara, GS, 1993
)
0.52
" No adverse side effects of the drug were observed among fish from any dosage group."( Efficacy of fumagillin against Thelohanellus kitauei infection of Israel carp, Cyprinus carpio nudus.
Kim, HC; Park, BK; Rhee, JK, 1993
)
0.66
" We observed a moderate dose-response effect for thiabendazole, whereby spore count decreased as drug consumption increased."( Effect of four antimicrobials against an Encephalitozoon sp. (Microsporidia) in a grasshopper host.
Johny, S; Whitman, DW, 2008
)
0.35
"Previously proved to be effective for treatment of microsporidial keratitis in humans, topical and subconjunctival concentration or dosing of fumagillin bicyclohexylamine failed to reduce corneal neovascularization induced by silver nitrate in this study."( Efficacy of fumagillin bicyclohexylamine on experimental corneal neovascularization in rat model.
Aşula, MF; Onur, IU; Yigit, FU, 2019
)
1.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
antibacterial drugA drug used to treat or prevent bacterial infections.
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
methionine aminopeptidase 2 inhibitorAny methionyl aminopeptidase inhibitor that inhibits the action of methionyl aminopeptidase 2.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
organooxygen heterocyclic antibiotic
meroterpenoidMeroterpenoids are complex organooxygen natural products produced from polyketide and terpenoid precursors.
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
antibiotic antifungal drugAny antibiotic antifungal agent used to treat fungal infections in humans or animals.
spiro-epoxideAn oxaspiro compound in which a carbon atom of an epoxide ring is the only common member of two rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency34.66543.189029.884159.4836AID1224846
TDP1 proteinHomo sapiens (human)Potency6.88470.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency43.27710.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency46.29010.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.08630.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency55.23500.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.53570.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency15.35530.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.83000.000229.305416,493.5996AID1259244; AID743075; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588534
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency13.68540.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency12.299819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency51.86760.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency38.94130.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.87230.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency6.11310.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency6.11310.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Methionine aminopeptidaseEscherichia coli K-12IC50 (µMol)100.00000.47203.50775.0000AID107914
Methionine aminopeptidase 2Homo sapiens (human)IC50 (µMol)0.00820.00060.96835.6000AID107580; AID107928; AID254943; AID424804
Methionine aminopeptidase 1Saccharomyces cerevisiae S288CIC50 (µMol)100.00007.00007.00007.0000AID107916
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (128)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
proteolysisMethionine aminopeptidaseEscherichia coli K-12
protein processingMethionine aminopeptidase 2Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 2Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
initiator methionyl aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
ferrous iron bindingMethionine aminopeptidaseEscherichia coli K-12
metalloexopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
metal ion bindingMethionine aminopeptidaseEscherichia coli K-12
metalloaminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
RNA bindingMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
protein bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolMethionine aminopeptidaseEscherichia coli K-12
cytosolMethionine aminopeptidaseEscherichia coli K-12
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytosolMethionine aminopeptidase 2Homo sapiens (human)
plasma membraneMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1127798Antiproliferative against HUVEC cells assessed as cell viability after 96 hrs by MTT assay2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID457163Antiangiogenic activity against HUVEC cells assessed as inhibition of vascular formation after 6 hrs by wound healing assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.
AID254943Inhibitory concentration against cobalt activated human methionine aminopeptidase 22005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.
AID248343Inhibitory concentration against Lymphoma EC4 cells measured for endothelial cell proliferation activity 2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Total synthesis and antiangiogenic activity of cyclopentane analogues of fumagillol.
AID107916Inhibitory activity against type I methionine aminopeptidase from Saccharomyces cerevisiae2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae.
AID604733Embryotoxicity in fertilized chicken embryo at 2.5 nmol/egg2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Concise synthesis and antiangiogenic activity of artemisinin-glycolipid hybrids on chorioallantoic membranes.
AID67454Tested in vitro for its ability to inhibit cell proliferation of lymphoma EL-4 cells measured calorimetrically by MTT method2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.
AID1127813Permeability in human HepG2 assessed as compound bound MetAP2 level at 0.1 uM by Western blotting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID448542Antiparasitic activity against Trypanosoma brucei 427 after 48 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antiparasitic activities of novel, orally available fumagillin analogs.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID424804Inhibition of methionine aminopeptidase 22009Journal of natural products, Mar-27, Volume: 72, Issue:3
A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products.
AID424803Inhibition of methionine aminopeptidase 12009Journal of natural products, Mar-27, Volume: 72, Issue:3
A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products.
AID1127805Antiproliferative against human HepG2 cells assessed as cell viability up to 1000 nM after 96 hrs by MTT assay2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID1127806Antiproliferative against human MCF7 cells assessed as cell viability up to 1000 nM after 96 hrs by MTT assay2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID1127812Permeability in HUVEC assessed as compound bound MetAP2 level at 0.1 uM by Western blotting analysis2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID41081Inhibition of endothelial cell ploriferation determined in bovine aortic endothelial cell (BAEC)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
AID590353Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Identification, structural properties and chelating capacity of miltipolone as a broad-spectrum inhibitor to cancer cells.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID546272Antiproliferative activity against human A549 cells after 96 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID546271Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1127804Antiproliferative against human Bel7402 cells assessed as cell viability up to 1000 nM after 96 hrs by MTT assay2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID546274Selectivity ratio of CC50 for human CCC-HPF1 cells to IC50 for HUVEC2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
AID154144Tested in vitro for its ability to inhibit cell proliferation of murine leukemia P388D1 cells measured calorimetrically by MTT method2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1654551Antiproliferative activity against human A2780 cells at 40 uM after 72 hrs by Cyquant assay
AID248803Inhibitory concentration against Calf pulmonary artery endothelial cells (CPAE) measured for endothelial cell proliferation activity 2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Total synthesis and antiangiogenic activity of cyclopentane analogues of fumagillol.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1127803Antiproliferative against human A549 cells assessed as cell viability up to 1000 nM after 96 hrs by MTT assay2013European journal of medicinal chemistry, , Volume: 70Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells.
AID262123Antiangiogenic activity at chorioallantoic membrane of chick embryo at 5 nmol per egg2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID546270Antiangiogenic activity in HUVEC after 96 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
AID1654553Cytotoxicity against HEK293 cells at 50 uM by SRB assay
AID546273Antiproliferative activity against human CCC-HPF1 cells after 96 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
AID107914Inhibitory activity against Methionine aminopeptidase 1 from Escherichia coli2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Discovery and structural modification of inhibitors of methionine aminopeptidases from Escherichia coli and Saccharomyces cerevisiae.
AID448541Antiparasitic activity against Plasmodium falciparum W2 infected in human erythrocytes after 72 hrs by FACS2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antiparasitic activities of novel, orally available fumagillin analogs.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID248394Inhibitory concentration against Murine leukemia P388 measured for endothelial cell proliferation activity 2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Total synthesis and antiangiogenic activity of cyclopentane analogues of fumagillol.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1654557Antibacterial activity against Escherichia coli ATCC 9637 at 50 ug/ml after 24 hrs by resazurin dye based broth microdilution method
AID457162Antiinvasive activity against mouse Colon 26-L5 assessed as inhibition of cell migration after 6 hrs by Matrigel assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.
AID98351Inhibitory activity against proliferation of murine leukemia (L1210) cells2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Novel bicyclic oxazolone derivatives as anti-angiogenic agents.
AID46864Tested in vitro for its ability to inhibit cell proliferation of calf pulmonary artery endothelial cells measured calorimetrically by SRB method2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.
AID107580In vitro inhibitory activity against purified recombinant human Methionine Aminopeptidase 2 (MetAP2)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID457168Antiinvasive activity against HUVEC assessed as inhibition of cell migration after 6 hrs by Matrigel assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID604734Antiangiogenesis activity against fertilized chicken egg chorioallantoic membrane assessed as inhibition of neovascularization at 2.5 nmol/egg by CAM vessel development assay relative to control2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Concise synthesis and antiangiogenic activity of artemisinin-glycolipid hybrids on chorioallantoic membranes.
AID8068Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Novel bicyclic oxazolone derivatives as anti-angiogenic agents.
AID107928Inhibitory activity against Methionine aminopeptidase 22004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Investigation of novel fumagillin analogues as angiogenesis inhibitors.
AID85312Tested for inhibition of the human umbilical vein endothelial cell (HUVEC) proliferation2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Investigation of novel fumagillin analogues as angiogenesis inhibitors.
AID1654556Antibacterial activity against Staphylococcus aureus ATCC 43300 at 50 ug/ml after 24 hrs by resazurin dye based broth microdilution method
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID448543Inhibition of human MetAP2 assessed as residual activity at 800 nM after 8 hrs by Met-AMC based fluorescence assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antiparasitic activities of novel, orally available fumagillin analogs.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID448540Antiparasitic activity against Entamoeba histolytica HMI:IMSS trophozoites after 60 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antiparasitic activities of novel, orally available fumagillin analogs.
AID42759Anti-angiogenic activity was assessed by inhibition of the vascular growth in the chick embryo chorioallantoic membrane (CAM assay) at 125 nM2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Novel bicyclic oxazolone derivatives as anti-angiogenic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (299)

TimeframeStudies, This Drug (%)All Drugs %
pre-199058 (19.40)18.7374
1990's42 (14.05)18.2507
2000's118 (39.46)29.6817
2010's70 (23.41)24.3611
2020's11 (3.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.95 (24.57)
Research Supply Index5.81 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index83.42 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (50.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.53%)5.53%
Reviews28 (8.59%)6.00%
Case Studies21 (6.44%)4.05%
Observational0 (0.00%)0.25%
Other272 (83.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]